Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Circadin, selv om det har vist sig kun at have en mindre virkning hos en relativ lille del af patienterne, er større end risiciene til korttidsbehandling af primær søvnløshed, karakteriseret ved dårlig søvnkvalitet hos patienter i alderen 55 år eller derover.
The Committee for Medicinal Products for Human Use (CHMP) decided that, although Circadin has been shown to have a small effect size in a relatively small fraction of patients, its benefits are greater than its risks for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.